Company Filing History:
Years Active: 2015-2017
Title: The Innovative Contributions of Andrew Beaton
Introduction
Andrew Beaton is a notable inventor based in Stevenage, GB. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of 2 patents, Beaton's work focuses on developing therapeutic solutions for diseases associated with TGF-beta signaling.
Latest Patents
Beaton's latest patents include groundbreaking research on nucleic acids encoding immunoglobulins that bind TGF-beta receptor II. The first patent discloses an anti-TGFbetaRII immunoglobulin single variable domain, which is characterized by an amino acid sequence that allows for up to five amino acid substitutions, deletions, or additions. This innovation aims to provide a polypeptide and pharmaceutical composition for treating various diseases, including tissue fibrosis, liver fibrosis, rheumatoid arthritis, and ocular disorders. The second patent also centers on single variable domain immunoglobulins that bind TGF-beta receptor II, further emphasizing the potential for treating conditions such as kidney fibrosis and scarring reduction.
Career Highlights
Andrew Beaton is currently associated with Glaxo Group Limited, where he continues to advance his research and development efforts. His work has positioned him as a key figure in the field of immunology, contributing to the understanding and treatment of complex diseases.
Collaborations
Beaton collaborates with esteemed colleagues, including Caroline Dimech and Peter Franz Ertl. These partnerships enhance the innovative potential of his research and contribute to the development of effective therapeutic solutions.
Conclusion
Andrew Beaton's contributions to immunology through his patents reflect his commitment to advancing medical science. His work not only addresses critical health issues but also showcases the importance of innovation in developing effective treatments.